Septerna (NASDAQ:SEPN) Price Target Raised to $40.00

Septerna (NASDAQ:SEPN) had its target price upped by HC Wainwright from $35.00 to $40.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

SEPN has been the subject of a number of other research reports. Truist Financial initiated coverage on Septerna in a report on Monday, December 15th. They set a “buy” rating and a $34.00 price objective for the company. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $28.00 in a report on Friday, November 14th. Wall Street Zen cut shares of Septerna from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 10th. Raymond James Financial assumed coverage on shares of Septerna in a research report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Septerna Price Performance

Shares of SEPN opened at $28.83 on Monday. The stock has a 50-day moving average of $26.91 and a 200-day moving average of $22.70. The company has a market cap of $1.29 billion, a PE ratio of -19.09 and a beta of 3.46. Septerna has a one year low of $4.66 and a one year high of $32.63.

Insider Activity

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at $5,046,834.73. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Samira Shaikhly sold 70,453 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $22,283.30. This represents a 98.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of hedge funds have recently made changes to their positions in SEPN. Deutsche Bank AG grew its position in Septerna by 5.3% during the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after buying an additional 744 shares during the period. Global Retirement Partners LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $35,000. Covestor Ltd increased its stake in shares of Septerna by 55.8% during the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after purchasing an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares during the last quarter. Finally, PharVision Advisers LLC grew its holdings in Septerna by 17.5% during the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.